Literature DB >> 2660896

Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation.

V Combaret1, M C Favrot, B Kremens, I Philip, C Bailly, B Fontaniere, O Gentilhomme, F Chauvin, J M Zucker, J L Bernard.   

Abstract

In about 50% of patients with stage IV neuroblastoma, micrometastases are present in the bone marrow when it is harvested for an autograft to follow induction therapy, and the risk of graft contamination by neuroblastoma cells has been the rationale for the use of a purging procedure. However, bone marrow metastases are detected with trephine biopsies which only explore the sites biopsied and do not reflect potential contamination of the pooled marrow harvested for autograft. A two-colour fluorochrome labelling method is described which permits as few as 1 neuroblastoma cell in 100,000 normal bone marrow cells from the autograft to be detected. Three monoclonal antibodies (UJ13A, H11 and 11.14) which react with neuroblastoma cells are used as single reagent in combination with a fourth anti-panleucocyte antibody. This method requires only 2 h for the analysis of three million marrow cells from the autograft, and is more effective than alkaline phosphatase staining with the same monoclonal antibodies. Results were compared with conventional techniques (four biopsies and four aspirates) carried out at the same time in 34 consecutive patients. Of 18 cases with negative aspirates and biopsies, neuroblastoma cells were detected in two autografts by the immunological method. Of 16 cases with positive aspirates and/or biopsies, 10 autografts were positive by the immunological method and six were negative. Thus, marrow micrometastases were detected in 16 of the 34 patients, but the autograft contained malignant cells in only 12 of these patients and the immunological analysis demonstrated that the use of a purging procedure allowed the elimination of neuroblastoma cells from the autograft before its reinjection to the patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660896      PMCID: PMC2246735          DOI: 10.1038/bjc.1989.180

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRc). Results of a four-institution Children's Cancer Study Group pilot study.

Authors:  G J D'Angio; C August; W Elkins; A E Evans; R Seeger; C Lenarsky; S Feig; J Wells; N Ramsay; T Kim
Journal:  Prog Clin Biol Res       Date:  1985

2.  Phenotypic and functional heterogeneity of human cloned natural killer cell lines.

Authors:  T Hercend; E L Reinherz; S Meuer; S F Schlossman; J Ritz
Journal:  Nature       Date:  1983-01-13       Impact factor: 49.962

3.  S-L 11.14: a monoclonal antibody recognizing neuroectodermal tumors with possible value for bone marrow purging before autograft.

Authors:  V Combaret; B Kremens; M C Favrot; J C Laurent; T Philip
Journal:  Bone Marrow Transplant       Date:  1988-05       Impact factor: 5.483

4.  High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma.

Authors:  J Graham-Pole; H M Lazarus; R H Herzig; S Gross; P Coccia; R Weiner; S Strandjord
Journal:  Am J Pediatr Hematol Oncol       Date:  1984

5.  Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution.

Authors:  C S August; F T Serota; P A Koch; E Burkey; H Schlesinger; W L Elkins; A E Evans; G J D'Angio
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

6.  Biological characterization and clinical applications of a monoclonal antibody recognizing an antigen restricted to neuroectodermal tissues.

Authors:  P M Allan; J A Garson; E I Harper; U Asser; H B Coakham; B Brownell; J T Kemshead
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

7.  Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres.

Authors:  J G Treleaven; F M Gibson; J Ugelstad; A Rembaum; T Philip; G D Caine; J T Kemshead
Journal:  Lancet       Date:  1984-01-14       Impact factor: 79.321

8.  Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies.

Authors:  I M Franklin; J Pritchard
Journal:  J Clin Pathol       Date:  1983-11       Impact factor: 3.411

9.  Diagnosis of human lymphoma with monoclonal antileukocyte antibodies.

Authors:  R A Warnke; K C Gatter; B Falini; P Hildreth; R E Woolston; K Pulford; J L Cordell; B Cohen; C De Wolf-Peeters; D Y Mason
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

10.  High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

Authors:  J Pritchard; T J McElwain; J Graham-Pole
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

View more
  6 in total

1.  Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker.

Authors:  A Schott; I Vogel; U Krueger; H Kalthoff; H W Schreiber; W Schmiegel; D Henne-Bruns; B Kremer; H Juhl
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

2.  Environmental cues from neural crest derivatives act as metastatic triggers in an embryonic neuroblastoma model.

Authors:  Dounia Ben Amar; Karine Thoinet; Benjamin Villalard; Olivier Imbaud; Clélia Costechareyre; Loraine Jarrosson; Florie Reynaud; Julia Novion Ducassou; Yohann Couté; Jean-François Brunet; Valérie Combaret; Nadège Corradini; Céline Delloye-Bourgeois; Valérie Castellani
Journal:  Nat Commun       Date:  2022-05-10       Impact factor: 17.694

3.  A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma.

Authors:  K Osmanagaoglu; M Lippens; Y Benoit; E Obrie; K Schelstraete; M Simons
Journal:  Eur J Nucl Med       Date:  1993-12

4.  Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.

Authors:  M Favrot; V Combaret; E Goillot; J P Wagner; E Bouffet; F Mazingue; A Thyss; P Bordigoni; G Delsol; C Bailly
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

5.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

6.  Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.

Authors:  T Philip; R Ladenstein; J M Zucker; R Pinkerton; E Bouffet; D Louis; W Siegert; J L Bernard; D Frappaz; C Coze
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.